Narrative review discusses screening and prevention in rheumatic and musculoskeletal disease populations.
Joint Pain May Signal Hidden Risk in Your Legs
This narrative review examines patients with rheumatic and musculoskeletal diseases (RMDs), including rheumatoid arthritis and systemic lupu…
Inflammation from autoimmune conditions can silently damage blood vessels in your legs.
Secukinumab improves skin response in Chinese patients with psoriatic arthritis
Secukinumab linked to skin improvement in Chinese psoriatic arthritis patients
This observational cohort study of 446 Chinese patients with psoriatic arthritis found that treatment with secukinumab for over 12 weeks was…
In Chinese psoriatic arthritis patients, secukinumab treatment was associated with significant skin improvement and better quality of life o…
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children.
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
The FDA has approved a new drug called Stelara for several inflammatory conditions.
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Phase III randomized clinical trials in 1,405 participants with psoriatic arthritis evaluated guselkumab treatment through week 100. The stu…
Pain scores for psoriatic arthritis strongly predict long-term joint damage, giving doctors clear numbers to track real progress and adjust …
Meta-analysis compares HAQ-DI, SF36-PF, and SF36-PCS for physical function in psoriatic arthritis trials
Which tool best tracks physical changes in psoriatic arthritis patients?
A meta-epidemiological study of 42 articles (31 RCTs) in psoriatic arthritis found HAQ-DI and SF36-PF were more responsive to change than SF…
Doctors can track psoriatic arthritis improvements more clearly with two specific tools that spot physical changes better than the third com…